Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

GS-US-540-5773 (Goldman)
  NCT04292899		 RCTremdesivirremdesivirCOVID-19 mild to moderatesome concern
200/197 suggested
  • suggested 53 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
GS-US-540-5774, 10 days
  NCT04292730		 RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
197/200 safety concern
  • suggested 58 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 88 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 63 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
The primary endpoint was not met, no odds ratio is reported because the proportional odds assumption was not met
GS-US-540-5774, 5 days
  NCT04292730		 RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
199/200 conclusif
  • demonstrated 65 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons